Journal Home > Volume 16 , Issue 1
Nano Biomedicine and Engineering 2024, 16(1): 64-77 https://doi.org/10.26599/NBE.2023.9290043
Review | Open Access | Issue | Published: 08 December 2023

Artificial Intelligence in the Paradigm Shift of Pharmaceutical Sciences: A Review

Show Author's Information Rahul S. Tade( ),  Swapnil N. Jain,  Janhavi T. Satyavijay,  Pratham N. Shah,  Tejaswi D. Bari,  Tanushri M. Patil,  Ruhi P. Shah
Department of Pharmaceutics, H.R. Patel Institute of Pharmaceutical Education and Research, Shirpur, Maharashtra 425405, India
Keywords:
drug discovery, artificial intelligence (AI), precision medicine, pharmaceutical research, academic research, job market
Cite this article:
Tade RS, Jain SN, Satyavijay JT, et al. Artificial Intelligence in the Paradigm Shift of Pharmaceutical Sciences: A Review. Nano Biomedicine and Engineering, 2024, 16(1): 64-77. https://doi.org/10.26599/NBE.2023.9290043
Download citation
EndNote(RIS)
BibTeX

745

Views

94

Downloads

Citations

0

Crossref

N/A

WoS

0

Scopus

N/A

CSCD

Abstract Full text About this article

AI has emerged as a revolutionary technology in the pharmaceutical and biomedical fields. This review explores its transformative role, particularly in drug development, the discovery of future interventions in the pharmaceutical sector. By leveraging AI, these processes have become more efficient, cost-effective, and capable of delivering personalized medicine to individual patients. Moreover, AI’s potential in disease prevention and outbreak prediction is promising, as it can analyze vast datasets to identify crucial patterns and trends, leading to targeted interventions for combating diseases. In biomedical research, AI has proven highly beneficial, especially in genomics, proteomics, and metabolomics, where it enables researchers to comprehensively analyze complex biological data, uncovering new insights and accelerating scientific discoveries. The impact of AI is also evident in the patient-physician interface, as it enhances diagnostic accuracy and treatment efficiency, ultimately improving patient care.


menu
Abstract
Full text
Outline
About this article

Artificial Intelligence in the Paradigm Shift of Pharmaceutical Sciences: A Review

Show Author's information Rahul S. Tade( ), Swapnil N. Jain, Janhavi T. Satyavijay, Pratham N. Shah, Tejaswi D. Bari, Tanushri M. Patil, Ruhi P. Shah
Department of Pharmaceutics, H.R. Patel Institute of Pharmaceutical Education and Research, Shirpur, Maharashtra 425405, India

Abstract

AI has emerged as a revolutionary technology in the pharmaceutical and biomedical fields. This review explores its transformative role, particularly in drug development, the discovery of future interventions in the pharmaceutical sector. By leveraging AI, these processes have become more efficient, cost-effective, and capable of delivering personalized medicine to individual patients. Moreover, AI’s potential in disease prevention and outbreak prediction is promising, as it can analyze vast datasets to identify crucial patterns and trends, leading to targeted interventions for combating diseases. In biomedical research, AI has proven highly beneficial, especially in genomics, proteomics, and metabolomics, where it enables researchers to comprehensively analyze complex biological data, uncovering new insights and accelerating scientific discoveries. The impact of AI is also evident in the patient-physician interface, as it enhances diagnostic accuracy and treatment efficiency, ultimately improving patient care.

Keywords: drug discovery, artificial intelligence (AI), precision medicine, pharmaceutical research, academic research, job market

References(63)

[1]

A. Zhavoronkov, Q. Vanhaelen, T.I. Oprea. Will artificial intelligence for drug discovery impact clinical pharmacology. Clinical Pharmacology &Therapeutics, 2020, 107(4): 780−785. https://doi.org/10.1002/cpt.1795
DOI Google Scholar
[2]

S. Vatansever, A. Schlessinger, D. Wacker, et al. Artificial intelligence and machine learning-aided drug discovery in central nervous system diseases: State-of-the-arts and future directions. Medicinal Research Reviews, 2021, 41(3): 1427−1473. https://doi.org/10.1002/med.21764
DOI Google Scholar
[3]

E.H. Weissler, T. Naumann, T. Andersson, et al. The role of machine learning in clinical research: Transforming the future of evidence generation. Trials, 2021, 22(1): 537. https://doi.org/10.1186/s13063-021-05489-x
DOI Google Scholar
[4]

K.K. Mak, M.K. Balijepalli, M.R. Pichika. Success stories of AI in drug discovery - where do things stand. Expert Opinion on Drug Discovery, 2022, 17(1): 79−92. https://doi.org/10.1080/17460441.2022.1985108
DOI Google Scholar
[5]

R. Dias, A. Torkamani. Artificial intelligence in clinical and genomic diagnostics. Genome Medicine, 2019, 11: 70. https://doi.org/10.1186/s13073-019-0689-8
DOI Google Scholar
[6]

R. Gupta, D. Srivastava, M. Sahu, et al. Artificial intelligence to deep learning: Machine intelligence approach for drug discovery. Molecular Diversity, 2021, 25: 1315−1360. https://doi.org/10.1007/s11030-021-10217-3
DOI Google Scholar
[7]

D. Paul, G. Sanap, S. Shenoy, et al. Artificial intelligence in drug discovery and development. Drug Discovery Today, 2021, 26(1): 80−93. https://doi.org/10.1016/j.drudis.2020.10.010
DOI Google Scholar
[8]

G. S. Liang, W. G. Fan, H. Luo, et al. The emerging roles of artificial intelligence in cancer drug development and precision therapy. Biomedicine &Pharmacotherapy, 2020, 128: 110255. https://doi.org/10.1016/j.biopha.2020.110255
DOI Google Scholar
[9]

K.-K. Mak, M.R. Pichika. Artificial intelligence in drug development: Present status and future prospects. Drug Discovery Today, 2019, 24(3): 773−780. https://doi.org/10.1016/j.drudis.2018.11.014
DOI Google Scholar
[10]

B.Y. Feng, A. Simeonov, A. Jadhav, et al. A high-throughput screen for aggregation-based inhibition in a large compound library. Journal of Medicinal Chemistry, 2007, 50(10): 2385−2390. https://doi.org/10.1021/jm061317y
DOI Google Scholar
[11]
M.B.M.A. Rashid, Artificial intelligence affecting a paradigm shifts in drug development. Slas Technology: SLAS Technology, 2021. 26(1): 3–15.
DOI
[12]

C. Selvaraj, I. Chandra, S.K. Singh. Artificial intelligence and machine learning approaches for drug design: Challenges and opportunities for the pharmaceutical industries. Molecular Diversity, 2022, 26(3): 1893−1913. https://doi.org/10.1007/s11030-021-10326-z
DOI Google Scholar
[13]

N. Stephenson, E. Shane, J. Chase, et al. Survey of machine learning techniques in drug discovery. Current Drug Metabolism, 2019, 20(3): 185−193. https://doi.org/10.2174/1389200219666180820112457
DOI Google Scholar
[14]

O. Khan, M. Parvez, P. Kumari, et al. The future of pharmacy: How AI is revolutionizing the industry. Intelligent Pharmacy, 2023, 1(1): 32−40. https://doi.org/10.1016/j.ipha.2023.04.008
DOI Google Scholar
[15]

P. Stone, M. Veloso. Multiagent systems: A survey from a machine learning perspective. Autonomous Robots, 2000, 8: 345−383. https://doi.org/10.1023/A:1008942012299
DOI Google Scholar
[16]

I. Donmez, S. Idin, S. Gulen. Conducting academic research with the AI interface ChatGPT: Challenges and opportunities. Journal of Steam Education, 2023, 6(2): 101−118.
Google Scholar
[17]

J.L. Ruiz-Real, J. Uribe-Toril, J.A. Torres, et al. Artificial intelligence in business and economics research: Trends and future. Journal of Business Economics and Management, 2020, 22(1): 98−117. https://doi.org/10.3846/jbem.2020.13641
DOI Google Scholar
[18]

M. Bhat, M. Rabindranath. The promise of artificial intelligence for predictive biomarkers in hepatology. Hepatology International, 2022, 16(3): 523−525. https://doi.org/10.1007/s12072-022-10342-7
DOI Google Scholar
[19]
V.B. Mathema, P. Sen, S. Lamichhane, et al. Deep learning facilitates multi-data type analysis and predictive biomarker discovery in cancer precision medicine. Computational and Structural Biotechnology Journal, 2023, 21: 1372–1382.
DOI
[20]

Z.Y. Low, I.A. Farouk, S.K. Lal. Drug repositioning: New approaches and future prospects for life-debilitating diseases and the COVID-19 pandemic outbreak. Viruses, 2020, 12(9): 1058. https://doi.org/10.3390/v12091058
DOI Google Scholar
[21]

X.Y. Zhu, Y. Li, N. Gu. Application of artificial intelligence in the exploration and optimization of biomedical nanomaterials. Nano Biomedicine and Engineering, 2023, 15: 342−353. https://doi.org/10.26599/NBE.2023.9290035
DOI Google Scholar
[22]
M. Rudrapal, S.J. Khairnar, A.G. Jadhav. Drug repurposing (DR): An emerging approach in drug discovery. In: Drug Repurposing - Hypothesis, Molecular Aspects and Therapeutic Applications. IntechOpen, 2020. https://doi.org/10.5772/intechopen.93193
DOI
[23]

A.V. Sadybekov, V. Katritch. Computational approaches streamlining drug discovery. Nature, 2023, 616(7958): 673−685. https://doi.org/10.1038/s41586-023-05905-z
DOI Google Scholar
[24]

M. Koromina, M.T. Pandi, G.P. Patrinos. Rethinking drug repositioning and development with artificial intelligence, machine learning, and omics. OMICS:A Journal of Integrative Biology, 2019, 23(11): 539−548. https://doi.org/10.1089/omi.2019.0151
DOI Google Scholar
[25]

J.M. Levin, T.I. Oprea, S. Davidovich, et al. Artificial intelligence, drug repurposing and peer review. Nature Biotechnology, 2020, 38(10): 1127−1131. https://doi.org/10.1038/s41587-020-0686-x
DOI Google Scholar
[26]

L.M. Williams, A.J. Rush, S.H. Koslow, et al. International Study to Predict Optimized Treatment for Depression (iSPOT-D), a randomized clinical trial: Rationale and protocol. Trials, 2011, 12: 4. https://doi.org/10.1186/1745-6215-12-4
DOI Google Scholar
[27]

S.K. Bhattamisra, P. Banerjee, P. Gupta, et al. Artificial intelligence in pharmaceutical and healthcare research. Big Data and Cognitive Computing, 2023, 7(1): 10. https://doi.org/10.3390/bdcc7010010
DOI Google Scholar
[28]

S. Graham, C. Depp, E.E. Lee, et al. Artificial intelligence for mental health and mental illnesses: An overview. Current Psychiatry Reports, 2019, 21(11): 116. https://doi.org/10.1007/s11920-019-1094-0
DOI Google Scholar
[29]

W.J. Yan, Q.N. Ruan, K. Jiang. Challenges for artificial intelligence in recognizing mental disorders. Diagnostics, 2022, 13(1): 2. https://doi.org/10.3390/diagnostics13010002
DOI Google Scholar
[30]

B. Bhinder, C. Gilvary, N.S. Madhukar, et al. Artificial intelligence in cancer research and precision medicine. Cancer Discovery, 2021, 11(4): 900−915. https://doi.org/10.1158/2159-8290.CD-21-0090
DOI Google Scholar
[31]

R. Hamamoto, K. Suvarna, M. Yamada, et al. Application of artificial intelligence technology in oncology: Towards the establishment of precision medicine. Cancers, 2020, 12(12): 3532. https://doi.org/10.3390/cancers12123532
DOI Google Scholar
[32]
N.M. Safdar, J.D. Banja, C.C. Meltzer. Ethical considerations in artificial intelligence. European Journal of Radiology, 2020, 122: 108768.
DOI
[33]

L. Surya. How government can use AI and ML to identify spreading infectious diseases. International Journal of Creative Research Thoughts, 2018, 6(1): 2320−2882.
Google Scholar
[34]

G. Russo, P. Reche, M. Pennisi, et al. The combination of artificial intelligence and systems biology for intelligent vaccine design. Expert Opinion on Drug Discovery, 2020, 15(11): 1267−1281. https://doi.org/10.1080/17460441.2020.1791076
DOI Google Scholar
[35]

J.L. Excler, M. Saville, S. Berkley, et al. Vaccine development for emerging infectious diseases. Nature Medicine, 2021, 27(4): 591−600. https://doi.org/10.1038/s41591-021-01301-0
DOI Google Scholar
[36]

A.S. Ahuja, V.P. Reddy, O. Marques. Artificial intelligence and COVID-19: A multidisciplinary approach. Integrative Medicine Research, 2020, 9(3): 100434. https://doi.org/10.1016%2Fj.imr.2020.100434
DOI Google Scholar
[37]

G. Arora, J. Joshi, R.S. Mandal, et al. Artificial intelligence in surveillance, diagnosis, drug discovery and vaccine development against COVID-19. Pathogens, 2021, 10(8): 1048. https://doi.org/10.3390/pathogens10081048
DOI Google Scholar
[38]

A. Hosny, C. Parmar, J. Quackenbush, et al. Artificial intelligence in radiology. Nature Reviews Cancer, 2018, 18(8): 500−510. https://doi.org/10.1038/s41568-018-0016-5
DOI Google Scholar
[39]

J.H. Thrall, X. Li, Q.Z. Li, et al. Artificial intelligence and machine learning in radiology: Opportunities, challenges, pitfalls, and criteria for success. Journal of the American College of Radiology, 2018, 15(3): 504−508. https://doi.org/10.1016/j.jacr.2017.12.026
DOI Google Scholar
[40]

M. Reyes, R. Meier, S. Pereira, et al. On the interpretability of artificial intelligence in radiology: Challenges and opportunities. Radiology:Artificial Intelligence, 2020, 2(3): e190043. https://doi.org/10.1148/ryai.2020190043
DOI Google Scholar
[41]

S. Saxena, B. Jena, N. Gupta, et al. Role of artificial intelligence in radiogenomics for cancers in the era of precision medicine. Cancers, 2022, 14(12): 2860. https://doi.org/10.3390/cancers14122860
DOI Google Scholar
[42]

J.W. Lao, Y.S. Chen, Z.C. Li, et al. A deep learning-based radiomics model for prediction of survival in glioblastoma multiforme. Scientific Reports, 2017, 7: 10353. https://doi.org/10.1038/s41598-017-10649-8
DOI Google Scholar
[43]
A.P. Brady, Neri, E. Artificial intelligence in radiology—Ethical considerations. Diagnostics, 2020, 10(4): 231.
DOI
[44]
He. The Impact of Artificial Intelligence (AI) on the Financial Job Market. Boston Consulting Group, 2018.
[45]

I. Kulkov. The role of artificial intelligence in business transformation: A case of pharmaceutical companies. Technology in Society, 2021, 66: 101629. https://doi.org/10.1016/j.techsoc.2021.101629
DOI Google Scholar
[46]

J. Sidlauskiene, Y. Joye, V. Auruskeviciene. AI-based chatbots in conversational commerce and their effects on product and price perceptions. Electronic Markets, 2023, 33: 24. https://doi.org/10.1007/s12525-023-00633-8
DOI Google Scholar
[47]

D. Khurana, A. Koli, K. Khatter, et al. Natural language processing: State of the art, current trends and challenges. Multimedia Tools and Applications, 2023, 82(3): 3713−3744. https://doi.org/10.1007/s11042-022-13428-4
DOI Google Scholar
[48]

L. Jenneboer, C. Herrando, E. Constantinides. The impact of chatbots on customer loyalty: A systematic literature review. Journal of Theoretical and Applied Electronic Commerce Research, 2022, 17(1): 212−229. https://doi.org/10.3390/jtaer17010011
DOI Google Scholar
[49]

M. Hasal, J. Nowaková, K. Ahmed Saghair, et al. Chatbots: Security, privacy, data protection, and social aspects. Concurrency and Computation:Practice and Experience, 2021, 33(19): e6426. https://doi.org/10.1002/cpe.6426
DOI Google Scholar
[50]

Y.N. Harari. Reboot for the AI revolution. Nature, 2017, 550(7676): 324−327. https://doi.org/10.1038/550324a
DOI Google Scholar
[51]

S. Livingston, M. Risse. The future impact of artificial intelligence on humans and human rights. Ethics &International Affairs, 2019, 33(2): 141−158. https://doi.org/10.1017/S089267941900011X
DOI Google Scholar
[52]
M. Gibbs, S. Bazylik. How is new technology changing job design? IZA World of Labor, 2017. Available at IZA World of Labor - How is new technology changing job design?
DOI
[53]

Y. K. Dwivedi, L. Hughes, E. Ismagilova, et al. Artificial Intelligence (AI): Multidisciplinary perspectives on emerging challenges, opportunities, and agenda for research, practice and policy. International Journal of Information Management, 2021, 57: 101994. https://doi.org/10.1016/j.ijinfomgt.2019.08.002
DOI Google Scholar
[54]
V.P. S. How can we manage biases in artificial intelligence systems - A systematic literature review. International Journal of Information Management Data Insights, 2023, 3(1): 100165.
DOI
[55]
C. Stiglic, P. Kocbek, N. Fijacko, et al. Interpretability of machine learning‐based prediction models in healthcare. Wiley Interdisciplinary Reviews: Data Mining and Knowledge Discovery, 2020. 10(5): e1379.
DOI
[56]

B. Meskó, E.J. Topol. The imperative for regulatory oversight of large language models (or generative AI) in healthcare. Npj Digital Medicine, 2023, 6: 120. https://doi.org/10.1038/s41746-023-00873-0
DOI Google Scholar
[57]

M. Braun, P. Hummel, S. Beck, et al. Primer on an ethics of AI-based decision support systems in the clinic. Journal of Medical Ethics, 2021, 47(12): e3. https://doi.org/10.1136/medethics-2019-105860
DOI Google Scholar
[58]

P. Schmidt, F. Biessmann, T. Teubner. Transparency and trust in artificial intelligence systems. Journal of Decision Systems, 2020, 29(4): 260−278. https://doi.org/10.1080/12460125.2020.1819094
DOI Google Scholar
[59]

N. Naik, B.M.Z. Hameed, D.K. Shetty, et al. Legal and ethical consideration in artificial intelligence in healthcare: Who takes responsibility. Frontiers in Surgery, 2022, 9: 862322. https://doi.org/10.3389/fsurg.2022.86232
DOI Google Scholar
[60]

C. González-Gonzalo, E.F. Thee, C.C.W. Klaver, et al. Trustworthy AI: Closing the gap between development and integration of AI systems in ophthalmic practice. Progress in Retinal and Eye Research, 2022, 90: 101034. https://doi.org/10.1016/j.preteyeres.2021.101034
DOI Google Scholar
[61]

M. Ayaz, M.F. Pasha, M.Y. Alzahrani, et al. The fast health interoperability resources (FHIR) standard: Systematic literature review of implementations, applications, challenges and opportunities. JMIR Medical Informatics, 2021, 9(8): e32869. https://doi.org/10.2196/21929
DOI Google Scholar
[62]

B.H.M. van der Velden, H.J. Kuijf, K.G.A. Gilhuijs, et al. Explainable artificial intelligence (XAI) in deep learning-based medical image analysis. Medical Image Analysis, 2022, 79: 102470. https://doi.org/10.1016/j.media.2022.102470
DOI Google Scholar
[63]

E.V. Bernstam, P.K. Shireman, F. Meric-Bernstam, et al. Artificial intelligence in clinical and translational science: Successes, challenges and opportunities. Clinical and Translational Science, 2022, 15(2): 309−321. https://doi.org/10.1111/cts.13175
DOI Google Scholar
Publication history
Copyright
Rights and permissions

Publication history

Received: 30 July 2023
Revised: 26 September 2023
Accepted: 19 October 2023
Published: 08 December 2023
Issue date: March 2024

Copyright

© The Author(s) 2024.

Rights and permissions

This is an open-access article distributed under  the  terms  of  the  Creative  Commons  Attribution  4.0 International  License (CC BY) (http://creativecommons.org/licenses/by/4.0/), which  permits  unrestricted  use,  distribution,  and reproduction in any medium, provided the original author and source are credited.

Return